Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors

• US 20040052785A1
• Filed: 07/09/2003
• Published: 03/18/2004
• Est. Priority Date: 01/09/2001
• Status: Abandoned Application

• Current Assignee: Merck Patent GmbH (Merck & Co., Inc.)
• Original Assignee: Merck Patent GmbH (Merck & Co., Inc.)
• Inventors: Goodman, Simon, Kreysch, Hans-Georg
• Application Number:
  US10/250,783
• Publication Number:
  US 20040052785A1
• Time in Patent Office: Days
• US Class Current: 424/143.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 41/0038 Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy radiotherapy per se A61N5/10
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/30 from tumour cells

Abstract

The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of receptor tyrosine kinase antagonists/inhibitors, especially ErbB receptor antagonists, more preferably EGF receptor (Her 1) antagonists and anti-angiogenic agents, preferably integrin antagonists, optionally together with agents or therapy forms that have additive or synergistic efficacy when administered together with said combination of antagonists/inhibitors, such as chemotherapeutic agents and or radiation therapy. The therapy can result in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.

Claims

1. A pharmaceutical composition comprising an agent or agents having

(i) at least one receptor tyrosine kinase blocking specificity and

(ii) at least one angiogenesis inhibiting specificity, wherein said agent or agents is/are not a cytokine immunoconjugate, optionally together with a pharmaceutically acceptable carrier, diluent or recipient.

2. A pharmaceutical composition of claim 1, further comprising a cytotoxic agent.

3. A pharmaceutical composition of claim 1 or 2, comprising

(i) at least one agent having a receptor tyrosine kinase blocking specificity, and

(ii) at least one agent having an angiogenesis inhibiting specificity.

4. A pharmaceutical composition of claim 1 or 2, comprising an agent having a receptor tyrosine kinase blocking specificity as well as an angiogenesis inhibiting specificity.

5. A pharmaceutical composition of claim 3, wherein said agent (i) has a ErbB receptor blocking specificity.

6. A pharmaceutical composition of claim 5, wherein the ErbB receptor specificity of said agent is related to the EGF receptor (ErbB1/Her1) or the ErbB2/Her2 receptor.

7. A pharmaceutical composition according to claim 6, wherein said agent is an antibody or a functionally intact derivative thereof, comprising a binding site which binds to an epitope of the ErbB1 (Her1) or Erb2(Her2) receptor.

8. A pharmaceutical composition according to claim 7, wherein said antibody or functionally intact derivative thereof is selected from the group:

humanized monoclonal antibody 425 (h425)

chimeric monoclonal antibody 225 (c225)

humanized monoclonal antibody Her 2.

9. A pharmaceutical composition according to any of the claims 1-8, wherein said angiogenesis inhibiting agent is an α

_vβ

₃, α

_vβ

₅ or an α

_vβ

₆ integrin inhibitor.

10. A pharmaceutical composition according to claim 9, wherein said integrin inhibitor is an RGD-containing linear or cyclic peptide.

11. A pharmaceutical composition according to claim 10, wherein said peptide is cyclo(Arg-Gly-Asp-DPhe-NMeVal).

12. A pharmaceutical composition according to claims 7 and 9, wherein said antibody or functionally intact derivative thereof is humanized monoclonal antibody 425 (h425) or chimeric monoclonal antibody 225 (c225) and said integrin inhibitor is cyclo(Arg-Gly-Asp-DPhe-NMeVal).

13. A pharmaceutical composition according to claim 12, further comprising a chemotherapeutic agent which is selected from any of the compounds of the group:

cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.

14. A pharmaceutical composition according to claim 9, wherein said integrin inhibitor is an antibody or a functionally intact derivative thereof, comprising a binding site which binds to an epitope of an integrin receptor.

15. A pharmaceutical composition according to claim 14, wherein said antibody is LM609 or P1F6.

16. A pharmaceutical composition according to claim 4, wherein said agent is a bispecific antibody or a heteroantibody molecule comprising a first binding site that binds to an epitope of a receptor tyrosine kinase and a second binding site that binds to an epitope of an angiogenesis receptor.

17. A pharmaceutical composition according to claim 16, wherein said bispecific antibody or heteroantibody molecule comprises a first binding site that binds to an epitope of an ErbB receptor and a second binding site that binds to an epitope of an integrin receptor.

18. A pharmaceutical composition according to claim 17, wherein said binding sites, which bind to an epitope of an ErbB receptor, are selected from monoclonal antibodies h425, c225 or Her 2, and said binding sites, which bind to an epitope of an integrin receptor, are selected from the monoclonal antibodies LM609 or P1F6.

19. A pharmaceutical composition according to claim 4, wherein said agent is an immunoconjugate consisting of an antibody or antibody fragment, bearing one of said specificities, and a non-immunological molecule, fused to the antibody or antibody fragment bearing the other specificity.

20. A pharmaceutical composition according to claim 19, wherein the antibody portion or fragment thereof comprises a binding site that binds to an epitope of an ErbB receptor, and the fused non-immunological molecule comprises a binding site that binds to an epitope of an integrin receptor.

21. A pharmaceutical composition according to claim 20, wherein said antibody portion which binds to an epitope of an ErbB receptor is selected from monoclonal antibodies h425, c225 or Her 2, and said non-imunological portion which binds to an epitope of an integrin receptor is cyclo(Arg-Gly-Asp-DPhe-NMeVal).

34. Use of a pharmaceutical composition or a pharmaceutical kit as defined in any of the claims 1-33, for the manufacture of a medicament to treat tumors and tumor metastases.

22. A pharmaceutical kit comprising

(i) a package comprising at least one ErbB receptor blocking agent, and

(ii) a package comprising at least one angiogenesis inhibiting agent.

23. A pharmaceutical kit of claim 22, further comprising a package comprising a cytotoxic agent.

25. The pharmaceutical kit of any of the claims 22-24, wherein said ErbB receptor blocking agent is an antibody or a functionally intact derivative thereof, having a binding site that binds to an epitope of said receptor.

26. A pharmaceutical kit of claim 25, wherein said antibody or functionally intact derivative thereof is selected from the group:

humanized monoclonal antibody 425 (h425), chimeric monoclonal antibody 225 (c225) or humanized monoclonal antibody Her 2.

27. A pharmaceutical kit of any of the claims 22-26, wherein said angiogenesis inhibiting agent is an α

_vβ

₃, α

_vβ

₅ or an α

_vβ

₆ integrin inhibitor.

28. A pharmaceutical kit of claim 27, wherein said integrin inhibitor is an RGD-containing linear or cyclic peptide.

29. A pharmaceutical kit of claim 28, wherein said peptide is cyclo(Arg-Gly-Asp-DPhe-NMeVal).

30. A pharmaceutical kit of any of the claims 22-26, wherein said angiogenesis inhibiting agent is an antibody or a functionally intact derivative thereof.

31. A pharmaceutical kit of claim 30, wherein said antibody is LM609 or P1F6.

32. A pharmaceutical kit of claim 22, comprising

(i) a package comprising humanized monoclonal antibody 425 (h425), chimeric monoclonal antibody 225 (c225), or a functionally intact derivative thereof, and

(ii) a package comprising cyclo(Arg-Gly-Asp-DPhe-NMeVal).

33. A pharmaceutical kit of claim 32, further comprising a chemotherapeutic agent which is selected from any of the compounds of the group:

cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin

24. A pharmaceutical kit comprising

(i) a package comprising at least one ErbB receptor blocking agent and at least one angiogenesis inhibiting agent, and

(ii) a package comprising a cytotoxic agent.

35. A method for treating tumors or tumor metastases in a patient comprising administering to said patient a therapeutically effective amount of an agent or agents having

(i) at least one receptor tyrosine kinase blocking specificity and

(ii) at least one angiogenesis inhibiting specificity,

wherein said agent or agents is/are not a cytokine immunoconjugate.

36. A method of claim 35, wherein additionally a cytotoxic agent is administered to the patient.

37. A method of claim 35 or 36, wherein said agent or agents have a receptor tyrosine kinase blocking specificity which is related to the ErbB receptor family.

38. A method of claim 37, wherein the ErbB receptor specificity of said agent is related to the EGF receptor (ErbB1/Her1) or the ErbB2/Her2 receptor.

39. A method of claim 38, wherein said agent is an antibody or a functionally intact derivative thereof, comprising a binding site which binds to an epitope of the ErbB1(Her1) or Erb2(Her2) receptor.

40. A method of claim 39, wherein said antibody or derivative thereof is selected from the group:

humanized monoclonal antibody 425 (h425), chimeric monoclonal antibody 225 (c225) or humanized monoclonal antibody Her 2.

41. A method of any of the claims 35-40, wherein said angiogenesis inhibiting agent is an α

_vβ

₃, α

_vβ

₅ or an α

_vβ

₆ integrin inhibitor or a VEGF receptor blocking agent.

42. A method of claim 41, comprising administering to the patient a therapeutically effective amount of (i) humanized monoclonal antibody 425 (h425) or chimeric monoclonal antibody 225 (c225), (ii) cyclo(Arg-Gly-Asp-DPhe-NMeVal), and optionally (iii) cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.